

# BMJ Open Compression hosiery to avoid post-thrombotic syndrome (CHAPS) protocol for a randomised controlled trial (ISRCTN73041168)

Ankur Thapar ,<sup>1,2,3</sup> Rebecca Lawton,<sup>1</sup> Laura Burgess,<sup>1</sup> Joseph Shalhoub,<sup>1</sup> Andrew Bradbury,<sup>4</sup> Nicky Cullum,<sup>5</sup> David Epstein,<sup>6</sup> Manjit Gohel,<sup>7</sup> Robert Horne,<sup>8</sup> Beverley J Hunt,<sup>9</sup> John Norrie,<sup>10</sup> A H Davies<sup>1</sup>

**To cite:** Thapar A, Lawton R, Burgess L, *et al.* Compression hosiery to avoid post-thrombotic syndrome (CHAPS) protocol for a randomised controlled trial (ISRCTN73041168). *BMJ Open* 2021;**11**:e044285. doi:10.1136/bmjopen-2020-044285

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2020-044285>).

Received 28 August 2020  
Revised 16 February 2021  
Accepted 09 March 2021

## ABSTRACT

**Introduction** Up to 50% of patients develop post-thrombotic syndrome (PTS) after an above knee deep vein thrombosis (DVT). The aim of the study was to determine the effect of graduated compression stockings in preventing PTS after DVT.

**Methods and analysis** Pragmatic, UK multicentre randomised trial in adults with first above knee DVT. The standard of care arm is anticoagulation. The intervention arm will receive anticoagulation plus stockings (European class II, 23–32 mm Hg compression) worn for a median of 18 months. The primary endpoint is PTS using the Villalta score. Analysis of this will be through a time to event approach and cumulative incidence at median 6, 12 and 18 months. An ongoing process evaluation will examine factors contributing to adherence to stockings to understand if and how the behavioural interventions were effective.

**Ethics and dissemination** UK research ethics committee approval (reference 19/L0/1585). Dissemination through the charity Thrombosis UK, the Imperial College London website, peer-reviewed publications and international conferences.

**Trial registration number** ISRCTN registration number 73041168.

## INTRODUCTION

Deep vein thrombosis (DVT) occurs in 1–2 per 1000 adults in the UK<sup>1</sup> and half will go on to develop lifelong disability from post-thrombotic syndrome (PTS).<sup>2</sup> PTS is defined as ‘chronic venous symptoms or signs secondary to deep vein thrombosis’<sup>3</sup> for example, leg pain, oedema and skin changes, progressing in 5% to ulceration. The average age of patients developing PTS is 55 years, meaning that most are of working age.<sup>4</sup> Individuals with PTS have difficulty walking and therefore maintaining employment, and have a level of disability comparable to chronic obstructive pulmonary disease.<sup>5</sup> The pathophysiology of PTS is sustained venous

## Strengths and limitations of this study

- Pragmatic multicentre randomised trial that will inform international practice.
- Stockings are a low cost, widely applicable, safe intervention across high and low resource healthcare systems.
- Assessor blind design.
- Examines behavioural factors affecting adherence.
- No placebo stocking arm due to ease of breaking blinding.

hypertension from venous outflow obstruction and valvular incompetence.<sup>6</sup>

The recent negative results of the ATTRACT trial have refocused attention on the effectiveness of graduated compression stockings (GCS) in preventing PTS.<sup>7</sup> The UK National Institute for Health and Care Excellence (NICE) and the American College of Chest Physicians recently withdrew their recommendations for the use of GCS in the prevention of PTS based on the results of the SOX trial.<sup>8 9</sup> However, European guidelines still recommend stockings.<sup>10 11</sup>

A recent systematic review examined randomised controlled trials (RCTs) in this area.<sup>12</sup> Three RCTs inclusive of 1177 patients examined the use of GCS providing 30–40 mm Hg compression at the ankle versus either no stocking,<sup>13 14</sup> or a placebo.<sup>4</sup> Follow-up ranged from 2 to 5 years with a primary outcome measure of cumulative incidence of PTS. There was important clinical, methodological and statistical heterogeneity between trials ( $I^2=94\%$ ). Key clinical differences were variable inclusion of patients with chronic venous disease, variable baseline rates of PTS and differing anatomy of DVT. Key methodological differences were the use of a placebo stocking versus a no stocking control arm,



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

## Correspondence to

Ankur Thapar;  
[a.thapar09@imperial.ac.uk](mailto:a.thapar09@imperial.ac.uk)

and differing PTS scoring systems.<sup>15</sup> Additionally, adherence varied between 56% and 93%.

The largest placebo-controlled trial showed no difference in the outcome of PTS with the use of stockings. The other two assessor blind trials showed absolute risk reductions of 23% and 39% with the use of stockings. There appeared to be more benefit from the use of GCS in populations with a higher baseline risk of PTS.<sup>12</sup>

Compression hosiery to avoid post-thrombotic syndrome (CHAPS) is a multicentre, pragmatic, assessor blind, RCT of adults with a first above knee DVT, comparing the regular use of a stocking with no stocking in preventing PTS.

PTS comprises a substantial economic burden on health systems, patients and society due to days lost to illness. The cost of three pairs of high-quality GCS per year is around £150, but this expense may be offset to some extent by lower costs elsewhere. Under standard care, around 50% of DVTs result in PTS.<sup>15</sup> Given the high cost of treatment of PTS, especially venous ulcers and the impact on quality of life,<sup>16</sup> the addition of GCS could be a cost-effective addition to standard treatment.

## METHODS AND ANALYSIS

CHAPS is a multicentre, pragmatic, assessor-blind superiority RCT. The trial will follow patients up for a median of 18 months (range 6–30 months). The study commenced on 1 May 2019 and is due to close on 31 January 2023. Please see [figure 1](#) for a Consolidated Standards of Reporting Trials diagram and online supplemental appendix 1 for a Standard Protocol Items: Recommendations for Interventional Trials checklist.

### Eligibility

[Table 1](#) details inclusion and exclusion criteria. Peripheral arterial disease will be screened for using pedal pulse palpation, with ankle brachial pressure index where equivocal.

### Recruitment

Recruitment will be from emergency departments, ambulatory care, DVT, vascular, obstetric or haematology clinics in 11 UK hospitals (see [www.ISCTRN.com](http://www.ISCTRN.com) for details), via the National Institute for Health Research (NIHR) Clinical Research Network and trial nurses. Recruitment of 864 participants is planned over 24 months from both academic and non-academic centres. Informed consent will be obtained in writing (online supplemental appendix 2) by the local study nurse.

### Study arms

#### Standard care

Anticoagulation for a minimum of 3 months (as per NICE recommendations<sup>8</sup>). The type and duration of anticoagulation beyond 3 months will be determined by local guidelines with the expectation that this will be a direct oral anticoagulant for the majority. A placebo stocking arm was

not included because of ease of breaking blinding. GCS are not recommended for treatment of acute leg pain.<sup>17</sup>

### Intervention arm

Anticoagulation plus a standardised below knee compression stocking (European class II, 23–32 mm Hg compression) worn during waking hours until the end of the trial, or until an alternative is required, for example, compression bandaging for venous ulceration. Minor variations such as change in fabric, open or closed toe or thigh length stockings are permissible if they aid adherence.

A number of behavioural aids will be made available to patients in the stocking arm:

- ▶ Patient education video at baseline
- ▶ Patient and carer refresher session for stocking donning and doffing within 2 weeks
- ▶ Free provision of a donning aid if required
- ▶ Cotton stocking for summer use

The following participant retention strategies have been employed:<sup>18</sup>

- ▶ Travel cost reimbursement
- ▶ Weekly text message reminders to wear stockings
- ▶ A Facebook support group for stocking wearers
- ▶ Next of kin contact for follow-up

Stockings will be fitted and issued by a local research nurse at first visit. Within 2 weeks, there will be a face-to-face or video call refresher session for donning and doffing with the research nurse, patient and carer.

### Randomisation

Participants will undergo 1:1 web-based randomisation by a local research nurse via the Research Electronic Data Capture (REDCap) database hosted at the Edinburgh Clinical Trials Unit.

### Primary effectiveness endpoint


The primary outcome measure is PTS as assessed by the recommended Villalta score at a median of 18 months follow-up.<sup>19</sup> This will be supplemented by a time to onset of PTS model.

### Secondary endpoints

1. Venous ulceration
2. Employment status (change in number of days working from baseline)
3. Quality of life measured using VEINES (Venous Insufficiency Epidemiological and Economic Study)-QoL and EuroQoL EQ5D scales
4. Adherence to stockings and anticoagulants
5. Cost-effectiveness of stocking prescription

### Sample size

The sample size calculation for CHAPS was based on the cumulative incidence of PTS at 18 months in the recent SOX trial.<sup>4</sup> A minimum clinically important difference of a 10% absolute risk reduction in PTS with GCS was chosen multifactorially, based on patient consultation, the degree of behaviour change required by patients and to be less than that found in earlier positive stocking trials (absolute



**Figure 1** CONSORT diagram. CONSORT, Consolidated Standards of Reporting Trials; NICE, National Institute for Health and Care Excellence. B-IPQ, Brief illness perception questionnaire; BSQ, Beliefs about stockings questionnaire; MARS, Medicine adherence rating scale; NICE CG 144, National Institute for Health and Clinical Excellence Clinical Guideline 144; QoL, Quality of life; TIQ, Treatment Intrusiveness Questionnaire; VEINES, Venous insufficiency epidemiological and economic study.

**Table 1** Eligibility criteria

<i>Inclusion criteria</i>	<i>Exclusion criteria</i>
Symptomatic presentation of first deep vein thrombosis, <2 weeks from diagnosis	Previously intolerant of or already wearing graduated compression stockings for more than 1 month
Imaging confirmed, lower limb deep vein thrombosis (popliteal, femoral, iliac or combination)	Contraindication to wearing graduated compression stockings or allergy to fabric
Ability to give informed consent	Life expectancy <2 years
Age 18 years or over	Ankle brachial pressure index <0.8 (measured when pedal pulses equivocal)
	Bilateral deep vein thrombosis
	Previous chronic venous insufficiency (patients with existing chronic skin changes or ulceration, defined as C4,5,6 by CEAP classification)
	Pre-existing post-thrombotic syndrome, significant leg pain (eg, knee arthritis, spinal claudication) or oedema (eg, lymphoedema)
	Newly diagnosed cancer, metastatic cancer or cancer undergoing active treatment or palliation
	Contraindication to anticoagulation

CEAP, Clinical, Etiological, Anatomical, Pathophysiological classification.

risk reduction 23%–39%),<sup>13 14</sup> reflecting improvements in anticoagulation. With 864 participants randomised 1:1, the study will have 90% power at a 5% level of significance using a test of binomial proportions to detect an absolute reduction in the incidence of PTS from 30% in the standard care arm to 20% in the intervention arm, allowing for 10% loss to follow-up. This reduction would represent a number needed to treat of 10 to prevent one case of PTS.

### Internal pilot study

An internal pilot study will follow a randomly selected group of 200 patients over the first 12 months, leading to a mixed-methods process evaluation of factors contributing to GCS adherence.

Adaptations of the Medication Adherence Rating Scale (MARS),<sup>20</sup> Brief Illness Perception Questionnaire (B-IPQ),<sup>21</sup> Treatment Intrusiveness Questionnaire (TIQ)<sup>22</sup> and a novel Beliefs about Stockings Questionnaire (BSQ) will be given to participants at the 1 month, 6 and 12 months and final follow-up assessments. Qualitative interviews from a purposive sample of 20 patients at 1 month and 7 months will be used to examine factors affecting GCS adherence in further depth.

### Trial stopping criteria

A combination of self-reported adherence and stocking reordering behaviour will be used to adjudicate adherence at the end of the pilot. The criteria for adequate 1 year adherence is  $\geq 70\%$  of participants in the intervention arm wearing the stocking for  $\geq 4$  days per week, with a documented stocking reorder in the last 6 months. This is the remit of the Trial Steering Committee (TSC). If this is achieved, the trial will continue into the main study. If this is not achieved, the trial will terminate and a process evaluation of factors influencing adherence will be reported.

### Assessment of outcomes and of blinding

The study is assessor blind. An independent researcher at each site will perform Villalta assessments blind to treatment allocation. Participants will remove their stockings on the night prior to their clinic visit and be instructed not to discuss stockings during their assessment. The following questionnaires will be administered at follow-up visits: EQ5D, VEINES-QoL and MARS. Employment status (average number of days per week currently working) and healthcare resource use (contacts and outcomes of interactions with health services) will also be collected. Data will be entered by the local research team onto the web-based database REDCap.

Blinding will be evaluated by asking assessors which arm they believe the participant is in. Unblinding is permissible only if a stocking-related significant adverse event is suspected.

### Data monitoring

In line with NIHR recommendations, a Trial Steering Committee (TSC) and an independent Data Monitoring Committee have been appointed to oversee trial conduct (please see online supplemental appendix 3). A Trial Manager together with the TSC will oversee trial progress. The study will be monitored by the Edinburgh Clinical Trials Unit to assess the progress of the study, verify adherence to the protocol and Good Clinical Practice guidelines and to review the completeness, accuracy and consistency of the data, through the use of independent data monitors. Pseudonymised data will be stored on REDCap, with a local key held by site Principal Investigators (PIs) to link this to clinical patient records. Data will be filed for 10 years as per local policy and then deleted.

### Data analysis

The primary analysis will be an intention-to-treat analysis that does not adjust for adherence to stockings. This will



be performed independently by the Edinburgh Clinical Trials Unit who will have sole access to the final REDCap data set. This will determine the treatment effect given the adherence in the trial, which is appropriate to gauge real-world effectiveness. The occurrence of PTS will be analysed in both a time-to-PTS approach (since it is possible that the treatment effect may both avert PTS, and also possibly delay its onset) and through analysis of cumulative incidence at a median of 6, 12 and 18 months (as recommended by the International Society for Thrombosis and Haemostasis and peer reviewers).<sup>3</sup> Prespecified subgroup analyses including iliac vein involvement and body mass index  $>30\text{ kg/m}^2$ . To determine the effect of optimum adherence (wearing a stocking for the trial duration for  $\geq 4$  days per week) on outcome, a secondary analysis will use Complier Average Causal Estimation modelling through instrumental variable regression. The results of the process evaluation will report which behavioural components change participants knowledge, beliefs and intentions regarding stocking usage. Participants who discontinue the study will have information until date of leaving available for analysis.

### Health economic analysis

Resource arising from the trial interventions, visits and admissions to hospital, general practice visits, community nursing and social and personal care will be collected during follow ups at 6 months, 12 months and the final visit and supplemented by case note review.

Employment status (average number of days worked per week, along with days lost from work and normal activities) will be collected from patients by questionnaire at baseline and at 6 months, 12 months and final follow-up.

A within-trial analysis and a decision model will be constructed. In both cases, the main analyses will be performed from the perspective of the UK NHS and Personal Social Services at 2018/2019 prices. Secondary analyses will be performed from a societal perspective. The results of the analyses will be presented as estimates of mean incremental costs, effects, and, incremental cost per quality-adjusted life year. Sensitivity analyses will be conducted to test the robustness of the results to alternative assumptions about model structure, assumptions and input data. Probabilistic sensitivity analysis will be conducted using Monte-Carlo simulation.

### Ethics and dissemination

The trial was granted ethical approval (National Research Ethics Service ref. 19/LO/1585).

Protocol amendments will be circulated by email to investigators and study nurses to cascade to participants. Dissemination of results will be by the CHAPS coinvestigators in peer-reviewed journals and international conferences and to a lay audience through the Thrombosis UK website.

### Adverse events and liability

All treatment-related adverse events will be collected by site PIs. The chief investigator (CI) will be notified of all serious adverse events within 24 hours. All serious adverse events

will be reported to the research ethics committee and sponsor, if, in the opinion of the CI, the event was related to the intervention. All related adverse events and serious adverse events will be recorded and summarised by treatment strategy. The sponsor (Imperial College London) holds a relevant insurance.

### Patient and public involvement

Patients, their carers' and relatives were involved in a three-stage consultation process during the trial development stage, incorporating NIHR INVOLVE methodology. This consisted of a series of semistructured interviews, a survey run via Thrombosis UK, and review of the CHAPS research plan and lay summary. Responses and feedback were incorporated into the design and budget of CHAPS. The Imperial Vascular PPI group has contributed four patients and two members of the public will advise the steering committee for the duration of the trial.

### CONCLUSION

The NIHR funded CHAPS trial will examine whether class II GCS prevent PTS, are cost-effective and the factors influencing adherence at a median 18 months follow-up (range 6–30 months).

### Author affiliations

<sup>1</sup>Academic Section of Vascular Surgery, Imperial College London, London, UK

<sup>2</sup>Faculty of Health Education, Medicine & Social Care, Anglia Ruskin University, Chelmsford, Essex, UK

<sup>3</sup>Vascular and Endovascular Surgery, Mid and South Essex Hospitals NHS Foundation Trust, Basildon, Essex, UK

<sup>4</sup>Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK

<sup>5</sup>School of Nursing, Midwifery and Social Work, The University of Manchester, Manchester, UK

<sup>6</sup>Faculty of Economic and Business Sciences, University of Granada, Granada, Andalucía, Spain

<sup>7</sup>Department of Vascular Surgery, Addenbrooke's Hospital, Cambridge, UK

<sup>8</sup>School of Pharmacy, University College London, London, UK

<sup>9</sup>Department of Haematology, Guy's & St Thomas' Foundation Trust, London, UK

<sup>10</sup>Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK

**Contributors** AT, JS, NC, MG, BJH developed the protocol and drafted the manuscript. RL and LB developed the PPI section and drafted the manuscript. DE developed the health economic section and drafted the manuscript. RH developed the adherence substudy and drafted the manuscript. JN drafted the manuscript, calculated the sample size calculation and constructed the data analysis plan. AHD is the overall project coordinator and drafted manuscript.

**Funding** This work was supported by the National Institute for Health Research (NIHR), Health Technology Assessment Programme, project number 17/147/47. The HTA Programme is funded by the NIHR, with contributions from the Chief Scientist Office in Scotland and National Institute for Social Care and Health Research in Wales and the Health and Social Care R&D Division, Public Health Agency in Northern Ireland. Sponsor: Imperial College London.

**Disclaimer** The views expressed in this publication are those of the authors and not necessarily those of the NHS, NIHR or the UK Department of Health and Social Care.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those

of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

#### ORCID iD

Ankur Thapar <http://orcid.org/0000-0003-4542-1100>

## REFERENCES

- 1 Raskob GE, Angchaisuksiri P, Blanco AN, *et al*. Thrombosis: a major contributor to the global disease burden. *J Thromb Haemost* 2014;12:1580–90.
- 2 Kahn SR, Shrier I, Julian JA, *et al*. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. *Ann Intern Med* 2008;149:698–707.
- 3 Kahn SR, Partsch H, Vedantham S, *et al*. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. *J Thromb Haemost* 2009;7:879–83.
- 4 Kahn SR, Shapiro S, Wells PS, *et al*. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. *Lancet* 2014;383:880–8.
- 5 Kahn SR, Shbaklo H, Lamping DL, *et al*. Determinants of health-related quality of life during the 2 years following deep vein thrombosis. *J Thromb Haemost* 2008;6:1105–12.
- 6 Kahn SR, Ginsberg JS. The post-thrombotic syndrome: current knowledge, controversies, and directions for future research. *Blood Rev* 2002;16:155–65.
- 7 Vedantham S, Goldhaber SZ, Julian JA, Magnuson E, Razavi MK, *et al*. Pharmacomechanical Catheter-Directed thrombolysis for deep-vein thrombosis. *N Engl J Med* 2017;377:2240–52.
- 8 NICE. *Venous thromboembolic diseases : CG144*, 2018.
- 9 Kearon C, Akl EA, Ornelas J, *et al*. Antithrombotic therapy for VTE disease: chest guideline and expert panel report. *Chest* 2016;149:315–52.
- 10 Rabe E, Partsch H, Hafner J, *et al*. Indications for medical compression stockings in venous and lymphatic disorders: an evidence-based consensus statement. *Phlebology* 2018;33:163–84.
- 11 Kakkos SK, Gohel M, Baekgaard N, *et al*. Editor's choice - European society for vascular surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. *Eur J Vasc Endovasc Surg* 2021;61:9–82.
- 12 Skervin AL, Thapar A, Franchini AJ, *et al*. Systematic review and meta-analysis of utility of graduated compression stockings in prevention of post-thrombotic syndrome. *Eur J Vasc Endovasc Surg* 2016;51:838–45.
- 13 Prandoni P, Lensing AWA, Prins MH, *et al*. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. *Ann Intern Med* 2004;141:249–57.
- 14 Brandjes DP, Büller HR, Heijboer H, *et al*. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. *Lancet* 1997;349:759–62.
- 15 Soosainathan A, Moore HM, Gohel MS, *et al*. Scoring systems for the post-thrombotic syndrome. *J Vasc Surg* 2013;57:254–61.
- 16 Epstein D, Gohel M, Heatley F, *et al*. Cost-effectiveness of treatments for superficial venous reflux in patients with chronic venous ulceration. *BJS Open* 2018;2:203–12.
- 17 Kahn SR, Shapiro S, Ducruet T, *et al*. Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial. *Thromb Haemost* 2014;112:1137–41.
- 18 Teague S, Youssef GJ, Macdonald JA, *et al*. Retention strategies in longitudinal cohort studies: a systematic review and meta-analysis. *BMC Med Res Methodol* 2018;18:1–22.
- 19 Kahn SR, Comerota AJ, Cushman M, *et al*. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American heart association. *Circulation* 2014;130:1636–61.
- 20 Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new medication adherence rating scale (MARS) for the psychoses. *Schizophr Res* 2000;42:241–7.
- 21 Broadbent E, Petrie KJ, Main J, *et al*. The brief illness perception questionnaire. *J Psychosom Res* 2006;60:631–7.
- 22 Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. *Psychol Health* 1999;14:1–24.
- 23 Cooper V, Horne R, Gellaitry G, *et al*. The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study. *J Acquir Immune Defic Syndr* 2010;53:369–77.



## SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Page	Item No	Description
<b>Administrative information</b>			
Title	1	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
Trial registration	1	2a	Trial identifier and registry name. If not yet registered, name of intended registry
		2b	All items from the World Health Organization Trial Registration Data Set
Protocol version	3	3	Date and version identifier
Funding	3	4	Sources and types of financial, material, and other support
Roles and responsibilities	4	5a	Names, affiliations, and roles of protocol contributors
	3	5b	Name and contact information for the trial sponsor
	3	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities
	App2	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
<b>Introduction</b>			
Background and rationale	7	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
	9	6b	Explanation for choice of comparators
Objectives	10	7	Specific objectives or hypotheses
Trial design	9	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)

**Methods: Participants, interventions, and outcomes**

Study setting	9	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility criteria	9	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
Interventions	9	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
	9	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
	9	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
	9	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
Outcomes	10	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
Participant timeline	15	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
Sample size	10	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
Recruitment	9	15	Strategies for achieving adequate participant enrolment to reach target sample size

**Methods: Assignment of interventions (for controlled trials)**

## Allocation:

Sequence generation	10	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions
---------------------	----	-----	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



Allocation concealment mechanism	10	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned
Implementation	10	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions
Blinding (masking)	11	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how
	11	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial

### Methods: Data collection, management, and analysis

Data collection methods	10,11	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol
	12	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols
Data management	12	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol
Statistical methods	12	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol
	12	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)
	12	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)

### Methods: Monitoring

Data monitoring	App2	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed
-----------------	------	-----	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

	11	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial
Harms	12	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct
Auditing	12	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor

### **Ethics and dissemination**

Research ethics approval	13	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval
Protocol amendments	13	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)
Consent or assent	9	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)
	9	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable
Confidentiality	12	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial
Declaration of interests	3	28	Financial and other competing interests for principal investigators for the overall trial and each study site
Access to data	12	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators
Ancillary and post-trial care	13	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation
Dissemination policy	13	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions
	13	31b	Authorship eligibility guidelines and any intended use of professional writers
	12	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code

**Appendices**

Informed consent materials	App1	32	Model consent form and other related documentation given to participants and authorised surrogates
Biological specimens	n.a	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

---

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

**CHAPS Trial Committees****Trial Steering Committee****Bold = independent member**

<b>Dr</b>	<b>Peter</b>	<b>MacCallum</b>	<b>Senior Lecturer in Haematology</b>	<b>Chair</b>
<b>Dr</b>	<b>Susie</b>	<b>Shapiro</b>	<b>Consultant Haematologist</b>	<b>Member</b>
<b>Mr</b>	<b>Isaac</b>	<b>Nyameke</b>	<b>Consultant Vascular Surgeon</b>	<b>Member</b>
<b>Dr</b>	<b>Stephen</b>	<b>Gerry</b>	<b>Senior medical statistician and NIHR doctoral research fellow</b>	<b>Member</b>
Professor	Alun	Davies	Professor of Vascular Surgery	Member
<b>Mr</b>	<b>Andrew</b>	<b>Steptowe</b>	<b>PPI member</b>	<b>Public Observer</b>
<b>Mr</b>	<b>David</b>	<b>Brae</b>	<b>PPI member</b>	<b>Public Observer</b>
Mr	Ankur	Thapar	Co-applicant	Observer
Professor	John	Norrie	Senior Statistician	Observer

**Data monitoring committee****Bold = independent member**

<b>Mr</b>	<b>Richard</b>	<b>Bulbulia</b>	<b>Consultant Vascular Surgeon</b>	<b>Chair</b>
<b>Dr</b>	<b>Natalie</b>	<b>Staplin</b>	<b>Senior Statistician – Renal Studies Group</b>	<b>Member</b>
<b>Mr</b>	<b>Richard</b>	<b>Haynes</b>	<b>Associate Professor</b>	<b>Member</b>
<b>Mr</b>	<b>Keith</b>	<b>Poskitt</b>	<b>Consultant Vascular and General Surgeon</b>	<b>Member</b>
Mr	Imad	Adamestam	Trial Statistician	



Delete this line, then print on



Hospital/Trust headed paper



**Compression Hosiery to Avoid Post-Thrombotic Syndrome  
(CHAPS)**

**ISRCTN: 73041168**

**HRA/REC Reference: 19/LO/1585**

**IRAS 263041**

**Sponsor Reference: 19CX5434**

***Acknowledgement***

*This project is funded by a National Institute for Health Research, Health Technology Assessment programme grant, which is funded by the National Institute for Health Research (NIHR)*

***Disclaimer***

*The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, NHS, NIHR or the Department of Health.*

Page 1 of 3

**CHAPS Patient Information Leaflet & Consent Form Version V3.0, 25/06/2020**

(Approved by REC: London - Bloomsbury on 04/08/2020)

**Delete this line, then print on Hospital/Trust headed paper**

Site ID:	Initials:
Participant Trial ID:	Principal Investigator Name:

**Compression Hosiery to Avoid Post-thrombotic Syndrome (CHAPS)**

**IRAS 263041**

**PATIENT CONSENT FORM**

Please initial box

1. I confirm that I have read and understand the information sheet dated 25/06/2020 (Version 3.0) for the above study and have had the opportunity to ask questions which have been answered fully. ☐
2. I understand that my participation is voluntary and that I am free to leave the study at any time without my medical care or legal rights being affected. ☐
3. I understand that relevant sections of my medical records may be looked at by authorised individuals from the research team, from regulatory bodies, from the study Sponsor, or from the NHS Trust in order to check that the study is being carried out correctly. I give permission, provided that strict confidentiality is maintained, for these bodies to have access to my medical records for the above study. ☐  
☐
4. I understand that my mobile phone number and email address will be stored until the end of the study securely by the University of Edinburgh and used to send weekly text message reminders to you until your participation on the study ends
5. I understand that my pseudonymised data will be transferred to the University Of Granada for the analysis. ☐
6. I agree to my data being entered onto a secure database held at the University of Edinburgh, in accordance with the Data Protection Act 2018. ☐
7. I agree to my GP, or any other doctor treating me, being notified of my participation in this study. I agree to my GP being involved in the study, including any necessary exchange of information about me between my GP and the research team. ☐

Page 2 of 3

**CHAPS Patient Information Leaflet & Consent Form Version V3.0, 25/06/2020**

(Approved by REC: London - Bloomsbury on 04/08/2020)

8. If during the study my clinical care team determine that I have lost capacity to provide informed consent, I will be withdrawn from the study and any identifiable data collected with consent would be retained and used in the study.

☐

9. I agree to take part in the CHAPS study.

☐

**Optional consent section (please initial the appropriate box)**

10. I give/do not give consent for information collected about me to be used to support other research in the future, including those outside of the EEA.

Give consent

☐

Do not give consent

☐

11. I give/do not give consent for my data may be linked with appropriate national databases, including Hospital Episode Statistics (HES), and the National Vascular Database as well as for longer term follow-up in the event the trial is extended

Give consent

☐

Do not give consent

☐

12. I give/do not give consent to be contacted in the future with regards to this study, should the study be extended.

Give consent

☐

Do not give consent

☐

\_\_\_\_\_  
Full Name of Participant

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Name of Person Taking  
Consent

\_\_\_\_\_  
Date

\_\_\_\_\_  
Signature

(1 copy for participant; 1 copy for the patient's medical notes, 1 copy for the site file)